Alkermes (ALKS) Other Operating Expenses (2010 - 2026)
Alkermes' (ALKS) quarterly Other Operating Expenses came in at $105.7 million in Q2 2026, up 1768.56% year-over-year from $5.7 million in Q2 2025, and up 402.34% quarter-over-quarter from $21.0 million in Q1 2026.
Analysis
Alkermes (ALKS) Other Operating Expenses (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Other Operating Expenses for 17 consecutive years, with $105.7 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Other Operating Expenses rose 1768.56% year-over-year to $105.7 million in Q2 2026; TTM through Jun 2026 was $163.4 million, a 254.29% increase from a year earlier, with the FY2025 full-year figure at $40.4 million, down 11.27% from the prior year.
- Other Operating Expenses was $105.7 million for Q2 2026 at Alkermes, up from $21.0 million in the prior quarter.
- Over five years, Other Operating Expenses peaked at $105.7 million in Q2 2026 and troughed at -$140.2 million in Q4 2023.
- A 5-year average of $15.3 million and a median of $17.7 million in 2025 frame the typical range for Other Operating Expenses.
- Across the five-year window, Other Operating Expenses sank 1591.94% in 2022 and jumped 8192.76% in 2023, its largest moves.
- Over 5 years, Other Operating Expenses stood at -$3.6 million in 2022, then sank by 3846.69% to -$140.2 million in 2023, then surged by 115.27% to $21.4 million in 2024, then declined by 11.4% to $19.0 million in 2025, then soared by 456.85% to $105.7 million in 2026.
- The last three Other Operating Expenses figures came in at $105.7 million (Q2 2026), $21.0 million (Q1 2026), and $19.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.32 Bn | 623.56 Bn | 17.26 Bn |
| 2 | AbbVie | 440.60 Bn | 434.04 Bn | 12.70 Bn |
| 3 | Merck | 365.39 Bn | 358.25 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn |
| 5 | Pfizer | 159.22 Bn | 147.52 Bn | 10.94 Bn |
| 6 | Sanofi | 52.48 Bn | 45.10 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.21 Bn | 44.21 Bn | - |
| 8 | Incyte | 25.34 Bn | 20.81 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.49 Bn | 18.82 Bn | 683.80 Mn |
| 10 | Alkermes | 7.58 Bn | 6.93 Bn | 397.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 105.67 Mn |
| Mar 31, 2026 | 21.04 Mn |
| Dec 31, 2025 | 18.98 Mn |
| Sep 30, 2025 | 17.70 Mn |
| Jun 30, 2025 | 5.66 Mn |
| Mar 31, 2025 | -1.92 Mn |
| Dec 31, 2024 | 21.42 Mn |
| Sep 30, 2024 | 20.96 Mn |
| Jun 30, 2024 | 1.47 Mn |
| Mar 31, 2024 | 1.70 Mn |
| Dec 31, 2023 | -140.23 Mn |
| Sep 30, 2023 | 70.49 Mn |
| Jun 30, 2023 | 72.15 Mn |
| Mar 31, 2023 | 66.96 Mn |
| Sep 30, 2022 | -3.55 Mn |
| Jun 30, 2022 | 870,000.00 |
| Mar 31, 2022 | -19.07 Mn |
| Dec 31, 2021 | -750,000.00 |
| Sep 30, 2021 | -5.20 Mn |
| Jun 30, 2021 | 3.24 Mn |